Eli Lilly and Company's bebtelovimab receives Emergency Use Authorization for the treatment of mild-to-moderate COVID-19
Posted:
FDA has authorized bebtelovimab for emergency use for certain non-hospitalized patients with mild-to-moderate COVID-19 at high risk of progression to severe disease for whom alternative COVID-19 treatment options approved or authorized by FDA are not accessible or clinically appropriate Bebtelovimab neutralizes Omicron as demonstrated by pseudovirus and authentic virus data.
Discover how Finland’s leading health technology hub is advancing digital healthcare through collaboration, research and innovation
The future of healthcare is being shaped by collaboration between researchers, technology pioneers, healthcare providers and businesses. In Oulu, Finland, this collaboration has created…
From AI-powered healthcare platforms to virtual hospitals, Abto Software is advancing the future of digital health
Healthcare is undergoing a rapid transformation, with technology playing a vital role in improving access to care, supporting clinicians, and enabling more personalised patient…